Altogether, to develop better therapies for PKU-disease, it is necessary to further investigate the regulatory mechanisms of USP19 alone or in combination with chaperones to elevate cellular protein levels in PAH variants such as F39l, P122Q, F161S, and I65T, which are all susceptible to rapid proteasomal degradation14. Here, USP19 is linked to pulmonary arterial hypertension.